PYA created a checklist for Life Science organizations as they engage key opinion leaders and healthcare professionals to help develop new medications and devices through participation in speaker programs, consulting roles, advisory boards, and other interactions. Read our tips & download the checklist ⬇️ https://lnkd.in/e-GYpb24
PYA’s Post
More Relevant Posts
-
📊 🔍 Dive deep into Allucent's upcoming webinar to learn how an interim analysis with sample size reassessment can mitigate risks. Whether it's uncertainty about effect size or intentional planning, discover both blinded and unblinded approaches to adjust sample size effectively. Don't miss out on this comprehensive exploration of sample size re-estimation and regulatory considerations in clinical research. ➡️ REGISTER HERE: https://buff.ly/49FHkgm Featured speakers: Lori Davis Allan Rosen #ClinicalTrials #SampleAnalysis #ClinicalResearch #SampleCollectio
-
-
The FDA is expanding the role of Patient Preference Information across the entire product life cycle, ensuring patient input drives medical innovation from start to finish. While challenges are expected, DHT.health is here to help you navigate through. Whether it's selecting the best patient preference methodology or addressing key study hurdles, we're committed to ensuring your research is patient-focused and impactful. 🙌 Find the article link in the comment 📝
-
#ICYMI: In this white paper, our experts analyzed what causes the early termination of clinical studies in pursuit of our overall goal to help sponsors improve their pipeline productivity. Read more: https://ow.ly/QFXO30sF2TO #SyneosHealth
-
-
#ICYMI: In this white paper, our experts analyzed what causes the early termination of clinical studies in pursuit of our overall goal to help sponsors improve their pipeline productivity. Read more: https://ow.ly/8ZTg30sF9Bz #SyneosHealth
-
-
Explore our 2023 Annual Report where we discuss how the integration of our research, development and commercialization efforts maximizes our impact for patients: https://bit.ly/4b0hi85.
-
-
#ICYMI: In this white paper, our experts analyzed what causes the early termination of clinical studies in pursuit of our overall goal to help sponsors improve their pipeline productivity. Read more: https://ow.ly/8ZTg30sF9Bz #SyneosHealth
-
-
GO get Greenphire's latest #WhitePaper revealing the real experiences and perspectives of those at the heart of #ClinicalResearch. Based off a 2024 survey of nearly 400 global sites, sponsors, and CROs we've captured the key factors driving clinical trial operations today. From technology preferences to the challenges of site management, this data uncovers the priorities guiding decisions across the industry. We dive deep into the survey findings, analyzing the preferences and obstacles that will influence clinical trial processes in the years to come. Access your copy: https://lnkd.in/eV68uZ3Y
-
-
Just a few reasons clinical trials can be delayed..... ⏳ Slower patient recruitment than expected ⏳⏳ Difficulty securing adequate comparator stock ✔✔✔Click the link in the article below to understand 3 immediate actions YOU can implement today to help solve clinical trial delays!! Lucy
Clinical trials face delays all too often. But in a competitive industry, where time-to-market is everything, keeping these delays to a minimum could be the difference between a market-leading product and one destined for the shadows. Solving clinical trial delays, according to McKinsey, where a second-to-market product will have a 6% market share disadvantage ten years later, is crucial for the financial success of the product. In the next of our series of articles from Business Development Director Ian Hoban, we look at "Solving Clinical Trial Delays." Click here https://bit.ly/3xtBIs6
-
-
In our latest video update, MoFo’s Daralyn Durie discusses her trial experience working within the life sciences and technology sectors. Learn more about the firm’s Life Sciences + Healthcare industry group. https://lnkd.in/enhp-Xwa
-
In our latest video update, MoFo’s Daralyn Durie discusses her trial experience working within the life sciences and technology sectors. Learn more about the firm’s Life Sciences + Healthcare industry group. https://lnkd.in/g5tu7z5t
